PMID- 38526919
OWN - NLM
STAT- MEDLINE
DCOM- 20240403
LR  - 20240428
IS  - 1473-558X (Electronic)
IS  - 0959-4965 (Linking)
VI  - 35
IP  - 6
DP  - 2024 Apr 3
TI  - CXCL13/CXCR5 promote chronic postsurgical pain and astrocyte activation in rats 
      by targeting NLRP3.
PG  - 406-412
LID - 10.1097/WNR.0000000000002023 [doi]
AB  - Chronic postsurgical pain (CPSP) with high incidence negatively impacts the 
      quality of life. X-C motif chemokine 13 (CXCL13) has been associated with 
      postsurgery inflammation and exacerbates neuropathic pain in patients with CPSP. 
      This study was aimed to illustrate the relationship between CXCL13 and nod-like 
      receptor protein-3 (NLRP3), which is also involved in CPSP. A CPSP model was 
      constructed by skin/muscle incision and retraction (SMIR) in right medial thigh, 
      and the rats were divided into three groups: Sham, SMIR, and SMIR + anti-CXCL13 
      (intrathecally injected with anti-CXCL13 antibody). Then, the paw withdrawal 
      threshold (PWT) score of rats was recorded. Primary rat astrocytes were isolated 
      and treated with recombinant protein CXCL13 with or without NLRP3 inhibitor 
      INF39. The expressions of CXCL13, CXCR5, IL-1beta, IL-18, GFAP, NLRP3, and Caspase-1 
      p20 were detected by real-time quantitative reverse transcription PCR, western 
      blot, ELISA, immunocytochemistry, and immunofluorescence analyses. The 
      anti-CXCL13 antibody alleviated SMIR-induced decreased PWT and increased 
      expression of GFAP, CXCL13, CXCR5, NLRP3, and Caspase-1 p20 in spinal cord 
      tissues. The production of IL-1beta, IL-18, and expression of CXCL13, CXCR5, GFAP, 
      NLRP3, and Caspase-1 p20 were increased in recombinant protein CXCL13-treated 
      primary rat astrocytes in a dose-dependent manner. Treatment with NLRP3 inhibitor 
      INF39 inhibited the function of recombinant protein CXCL13 in primary rat 
      astrocytes. The CXCL13/CXCR5 signaling could promote neuropathic pain, astrocytes 
      activation, and NLRP3 inflammasome activation in CPSP model rats by targeting 
      NLRP3. NLRP3 may be a potential target for the management of CPSP.
CI  - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Yi, Hongda
AU  - Yi H
AD  - Department of Anesthesiology, Hangzhou Women's Hospital, Hangzhou, China.
FAU - Zhu, Bin
AU  - Zhu B
FAU - Zheng, Caihong
AU  - Zheng C
FAU - Ying, Zhenyang
AU  - Ying Z
FAU - Cheng, Mei
AU  - Cheng M
LA  - eng
PT  - Journal Article
DEP - 20240307
PL  - England
TA  - Neuroreport
JT  - Neuroreport
JID - 9100935
RN  - EC 3.4.22.- (Caspases)
RN  - 0 (Chemokine CXCL13)
RN  - 0 (CXCL13 protein, human)
RN  - 0 (CXCR5 protein, human)
RN  - 0 (Interleukin-18)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
RN  - 0 (Receptors, CXCR5)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Animals
MH  - Rats
MH  - Astrocytes/metabolism
MH  - Caspases
MH  - *Chemokine CXCL13/metabolism
MH  - Interleukin-18
MH  - *Neuralgia/metabolism
MH  - *NLR Family, Pyrin Domain-Containing 3 Protein/metabolism
MH  - *Pain, Postoperative/metabolism
MH  - Rats, Sprague-Dawley
MH  - *Receptors, CXCR5/metabolism
MH  - Recombinant Proteins
EDAT- 2024/03/25 18:41
MHDA- 2024/04/03 06:44
CRDT- 2024/03/25 12:53
PHST- 2024/04/03 06:44 [medline]
PHST- 2024/03/25 18:41 [pubmed]
PHST- 2024/03/25 12:53 [entrez]
AID - 00001756-202404010-00004 [pii]
AID - 10.1097/WNR.0000000000002023 [doi]
PST - ppublish
SO  - Neuroreport. 2024 Apr 3;35(6):406-412. doi: 10.1097/WNR.0000000000002023. Epub 
      2024 Mar 7.